Verici Dx validated a 29-gene immune RNA expression signature to predict acute kidney rejection risk before transplantation, independent of donor factors and standard clinical risk markers. The company’s Pre-Transplant Risk Assessment (PTRA) assay, tested in a prospective clinical study, was published in Kidney360. The approach addresses an unmet need in transplant workflow planning, where most rejection testing focuses on post-transplant measurements. By contrast, PTRA stratifies recipients as high or low risk using blood-based gene regulatory pathway signals collected pre-operatively. The immediate impact is improved patient and transplant management decision support—while the longer-term market depends on regulatory clearance timelines and real-world clinical utility versus existing post-transplant assays.